Cullinan Oncology Inc Stock

$7.90

2.46% yesterday

Nasdaq, May 20, 10:00 pm CET

ISIN

US2300311063

Symbol

CGEM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Cullinan Oncology Inc Stock price

$7.90

-13.10 62.38% 5Y

Nasdaq, Closing price Tue, May 20 2025

+0.19 2.46%

ISIN

US2300311063

Symbol

CGEM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$466.22m
Enterprise Value	$164.23m
P/E (TTM) P/E ratio	negative
P/B ratio (TTM) P/B ratio	0.84
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-208.93m
Cash position	$303.83m
EPS (TTM) EPS	$-3.10
P/E forward	negative
P/S forward	64.55
EV/Sales forward	22.74
Short interest	14.66%

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Get Started for Free Today

Cullinan Oncology Inc Stock Analysis

Unlock Scores for Free

??

10 Analysts have issued a Cullinan Oncology Inc forecast:

10x Buy

100%

More details on Analyst Estimates Including Price Targets

10 Analysts have issued a Cullinan Oncology Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Cullinan Oncology Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	0.31 0.31	0% 0% -
Gross Profit	-0.31 -0.31	0% 0% -
- Selling and Administrative Expenses	55 55	25% 25% -
- Research and Development Expense	154 154	21% 21% -
EBITDA	-209 -209	22% 22% -
- Depreciation and Amortization	0.31 0.31	0% 0% -
EBIT (Operating Income) EBIT	-209 -209	22% 22% -
Net Profit	-179 -179	35% 35% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Cullinan Oncology Inc Stock News

Neutral

GlobeNewsWire

●

13 days ago

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025

Neutral

GlobeNewsWire

●

22 days ago

Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren's Disease in the United States

CLN-978 is the first and only development-stage CD19 T cell engager to receive U.S. FDA IND clearance in autoimmune diseases Sjögren's disease represents the third indication under development for CLN-978, and is a disease with high unmet need and no currently approved therapies CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical ...

Neutral

GlobeNewsWire

●

28 days ago

Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025

Cullinan and Taiho previously announced the Phase 2b portion of the study met the primary endpoint of overall response rate Cullinan and Taiho previously announced the Phase 2b portion of the study met the primary endpoint of overall response rate

More Cullinan Oncology Inc News

Company Profile

Cullinan Oncology, Inc. is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on 15 September, 2016 and is headquartered in Cambridge, MA.

Head office	United States
CEO	Nadim Ahmed
Employees	111
Founded	2016
Website	www.cullinantherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now